FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076186287> ?p ?o ?g. }

• W2076186287 endingPage "465" @default.
• W2076186287 startingPage "457" @default.
• W2076186287 abstract "Abstract Background Currently, acyclovir ( ACV ) at 1000 mg/day is widely used as prophylaxis in the early phase of hematopoietic stem cell transplant ( HSCT ) in Japan. However, low‐dose ACV (200 mg/day) has been shown to prevent varicella zoster virus reactivation in the middle and late phases of HSCT . Methods Therefore, in this study, we decreased the dose of ACV to 200 mg/day in the early phase after HSCT . We analyzed 93 consecutive herpes simplex virus ( HSV )‐seropositive patients who underwent allogeneic HSCT for the first time in our center between J une 2007 and D ecember 2011. Results Before A ugust 2009, 38 patients received oral ACV at 1000 mg/day ( ACV 1000) until day 35 after HSCT , whereas 55 patients received oral ACV at 200 mg/day ( ACV 200) after S eptember 2009. We compared the cumulative incidence of HSV infection in the 2 groups. Oral ACV was changed to intravenous administration because of intolerance in 66% and 45% of the patients in the ACV 1000 and ACV 200 groups, respectively ( P = 0.060). The probability of severe stomatitis (Bearman grade II – III ) was 76% and 60% in the ACV 1000 and ACV 200 groups, respectively ( P = 0.12). The number of patients who developed HSV disease before day 100 after HSCT was 0 in the ACV 1000 group and 2 in the ACV 200 group, with a cumulative incidence of 3.6% ( P = 0.43). HSV disease in the latter 2 patients was limited to the lips and tongue and was successfully treated with ACV or valacyclovir at a treatment dose. Conclusion ACV at 200 mg/day appeared to be effective for preventing HSV disease in the early phase after HSCT ." @default.
• W2076186287 created "2016-06-24" @default.
• W2076186287 creator A5003368425 @default.
• W2076186287 creator A5006679141 @default.
• W2076186287 creator A5015730300 @default.
• W2076186287 creator A5016842015 @default.
• W2076186287 creator A5017767691 @default.
• W2076186287 creator A5020380469 @default.
• W2076186287 creator A5027423432 @default.
• W2076186287 creator A5030408468 @default.
• W2076186287 creator A5033204118 @default.
• W2076186287 creator A5046470991 @default.
• W2076186287 creator A5047768108 @default.
• W2076186287 creator A5060000097 @default.
• W2076186287 creator A5062463606 @default.
• W2076186287 creator A5067604014 @default.
• W2076186287 creator A5068184151 @default.
• W2076186287 creator A5072057890 @default.
• W2076186287 creator A5072808833 @default.
• W2076186287 date "2013-07-29" @default.
• W2076186287 modified "2023-10-09" @default.
• W2076186287 title "Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation" @default.
• W2076186287 cites W1954992673 @default.
• W2076186287 cites W1967027894 @default.
• W2076186287 cites W1969149822 @default.
• W2076186287 cites W1973617793 @default.
• W2076186287 cites W1977314954 @default.
• W2076186287 cites W1983540655 @default.
• W2076186287 cites W1996999066 @default.
• W2076186287 cites W2000452027 @default.
• W2076186287 cites W2012284605 @default.
• W2076186287 cites W2014050941 @default.
• W2076186287 cites W2021314445 @default.
• W2076186287 cites W2035218440 @default.
• W2076186287 cites W2038981426 @default.
• W2076186287 cites W2060205983 @default.
• W2076186287 cites W2063223829 @default.
• W2076186287 cites W2081134784 @default.
• W2076186287 cites W2090765690 @default.
• W2076186287 cites W2101492913 @default.
• W2076186287 cites W2121960517 @default.
• W2076186287 cites W2145781384 @default.
• W2076186287 cites W2337976486 @default.
• W2076186287 doi "https://doi.org/10.1111/tid.12118" @default.
• W2076186287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23895431" @default.
• W2076186287 hasPublicationYear "2013" @default.
• W2076186287 type Work @default.
• W2076186287 sameAs 2076186287 @default.
• W2076186287 citedByCount "17" @default.
• W2076186287 countsByYear W20761862872015 @default.
• W2076186287 countsByYear W20761862872016 @default.
• W2076186287 countsByYear W20761862872017 @default.
• W2076186287 countsByYear W20761862872018 @default.
• W2076186287 countsByYear W20761862872019 @default.
• W2076186287 countsByYear W20761862872020 @default.
• W2076186287 countsByYear W20761862872021 @default.
• W2076186287 countsByYear W20761862872022 @default.
• W2076186287 crossrefType "journal-article" @default.
• W2076186287 hasAuthorship W2076186287A5003368425 @default.
• W2076186287 hasAuthorship W2076186287A5006679141 @default.
• W2076186287 hasAuthorship W2076186287A5015730300 @default.
• W2076186287 hasAuthorship W2076186287A5016842015 @default.
• W2076186287 hasAuthorship W2076186287A5017767691 @default.
• W2076186287 hasAuthorship W2076186287A5020380469 @default.
• W2076186287 hasAuthorship W2076186287A5027423432 @default.
• W2076186287 hasAuthorship W2076186287A5030408468 @default.
• W2076186287 hasAuthorship W2076186287A5033204118 @default.
• W2076186287 hasAuthorship W2076186287A5046470991 @default.
• W2076186287 hasAuthorship W2076186287A5047768108 @default.
• W2076186287 hasAuthorship W2076186287A5060000097 @default.
• W2076186287 hasAuthorship W2076186287A5062463606 @default.
• W2076186287 hasAuthorship W2076186287A5067604014 @default.
• W2076186287 hasAuthorship W2076186287A5068184151 @default.
• W2076186287 hasAuthorship W2076186287A5072057890 @default.
• W2076186287 hasAuthorship W2076186287A5072808833 @default.
• W2076186287 hasConcept C120665830 @default.
• W2076186287 hasConcept C121332964 @default.
• W2076186287 hasConcept C126322002 @default.
• W2076186287 hasConcept C197934379 @default.
• W2076186287 hasConcept C203014093 @default.
• W2076186287 hasConcept C2522874641 @default.
• W2076186287 hasConcept C2776409557 @default.
• W2076186287 hasConcept C2777408962 @default.
• W2076186287 hasConcept C2779051857 @default.
• W2076186287 hasConcept C2779450786 @default.
• W2076186287 hasConcept C2780727368 @default.
• W2076186287 hasConcept C2781196997 @default.
• W2076186287 hasConcept C2911091166 @default.
• W2076186287 hasConcept C61511704 @default.
• W2076186287 hasConcept C71924100 @default.
• W2076186287 hasConcept C88879693 @default.
• W2076186287 hasConcept C90924648 @default.
• W2076186287 hasConceptScore W2076186287C120665830 @default.
• W2076186287 hasConceptScore W2076186287C121332964 @default.
• W2076186287 hasConceptScore W2076186287C126322002 @default.
• W2076186287 hasConceptScore W2076186287C197934379 @default.
• W2076186287 hasConceptScore W2076186287C203014093 @default.
• W2076186287 hasConceptScore W2076186287C2522874641 @default.

• next